Physician profile
Ross E Lipton
NPI 1518256767
$7,318.80
in general payments reported to CMS, 2019-2025
58 companies · $23.19 in 2025
The $23.19 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $982 · 2021: $1,535 · 2022: $1,063 · 2023: $1,251 · 2024: $994 · 2025: $23.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,394.86 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.01 | 2019-2024 | Relistor |
| Lundbeck LLC | $429.63 | 2020-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $363.54 | 2019-2025 | Ztlido |
| Daiichi Sankyo INC. | $354.25 | 2019 | |
| Biodelivery Sciences International, INC. | $305.21 | 2019-2021 | |
| Allergan, INC. | $252.01 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $240.14 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $201.78 | 2019-2023 | Belbuca |
| Virtus Pharmaceuticals LLC | $187.34 | 2020-2021 | |
| Forte Bio-Pharma LLC | $185.76 | 2021-2023 | Prolate, Nalocet |
| Pfizer INC. | $180.01 | 2019-2024 | |
| Amgen INC. | $163.67 | 2019-2021 | |
| Nevro Corp. | $161.44 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $160.72 | 2022-2023 | Seglentis |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Lipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.